FIG 5.

Association between BRCA1/2 biallelic alteration and genome-wide loss of heterozygosity (gLOH) score as a continuous variable. gLOH score was assessed in (A) BRCA1/2, (B) BRCA1, and (C) BRCA2 biallelic v wild-type cases across cancer types. Boxes span the first and third quartiles, and the median is denoted by the horizontal line in the box; whiskers indicate maximum and minimum values within 1.5× the interquartile range; black dots indicate outlier events. P values are by Mann-Whitney U test for comparison between biallelic and wild-type BRCA1/2 cases. *P < .05, **P < .01, ***P < .001 (see Data Supplement). CUP, cancer of unknown primary; HNSCC, head and neck squamous cell carcinoma; NSCLC, non–small-cell lung cancer; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; UC, urothelial cancer.